Postpyloric feedings to improve lung health in preterm infants
Official title: A Randomized Controlled Crossover Trial of Postpyloric Versus Gastric Feedings to Improve Pulmonary Outcomes in High-risk Preterm Infants
Run by Boston Children's Hospital · NCT05777512 · Data updated 2026-11-12
This study is testing if feeding preterm infants directly into their intestines can help improve their lung health better than regular feeding through the nose.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 0 Hours to 1 Year |
| Sex | All |
| Enrollment | 50 (estimated) |
| Sponsor | Boston Children's Hospital Academic / other |
| Locations | 1 site (Boston, Massachusetts) |
| Status | Recruiting |
| Started | April 26, 2024 |
| Main results expected | September 2027 |
| Study ends | February 2028 |
| Registry record updated | June 29, 2026 |
| Trial ID | NCT05777512 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are preterm infants born before 32 weeks' gestation who require respiratory support and are tolerating enteral feedings.
✕Probably not a fit
Patients who are on temporary respiratory support for reasons unrelated to lung disease from prematurity may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study aims to evaluate whether postpyloric feedings can enhance pulmonary health in preterm infants suffering from bronchopulmonary dysplasia compared to traditional nasogastric feedings. It employs a randomized controlled crossover design, where each participant will experience both feeding methods in separate blocks. The study will assess clinical outcomes and biomarkers to determine the effectiveness of the feeding approach in reducing lung disease severity. By focusing on high-risk infants, the research seeks to optimize nutritional management and improve overall respiratory outcomes.
Why it matters
Potential benefit: If successful, this study could lead to improved pulmonary health and reduced complications for preterm infants with chronic lung disease.
How similar studies have gone: While the approach of using postpyloric feedings is innovative, similar studies have not been widely conducted, making this a novel investigation.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: Preterm infants born \< 32 weeks' gestation may enroll at 34-44 weeks post-menstrual age, who: 1. Remain on either invasive ventilation or non-invasive ventilation (continuous positive airway pressure or nasal intermittent positive pressure ventilation) for minimum 48 hours at the time of study entry. The minimum support required for inclusion is CPAP \> 5cm H2O or CPAP 5 with FiO2 \> 21%. 2. Have ongoing need for respiratory support due to underlying lung disease from prematurity. 3. Are tolerating \> 80 ml/kg/day of enteral feedings at baseline, either via nasogastric (NG) or nasojejunal (NJ) tube. Patients may be receiving gastric (NG) or postpyloric (NJ) feedings. Exclusion Criteria: 1. Infants who are transiently on respiratory support at the time of study entry due to another reason than underlying lung disease from prematurity; for example, recovery from a surgical intervention. 2. Infants who have other comorbidities that significantly contribute to lung disease, including cyanotic congenital heart disease, or other genetic, congenital, or pulmonary abnormalities. 3. Infants who were evaluated for necrotizing enterocolitis (including holding feedings) in the 7 days prior to study enrollment. 4. Infants with known gastrointestinal or airway malformations that would affect tolerance of feeds or the route of delivery of enteral feedings.
Where it's running
-
Boston Children's Hospital
Boston, Massachusetts, United States Recruiting
Study contacts
- Principal investigator: Jonathan Levin, MD — Boston Children's Hospital
- Study coordinator: Jonathan Levin, MD
- Email: jonathan.levin@childrens.harvard.edu
- Phone: 617-355-1900
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Lung Ultrasound Score to predict BPD in very preterm babies
This study tests whether lung ultrasound scores in the first two weeks of life can predict which extremely preterm babies will develop bronchopulmonary dysplasia.
-
Caffeine in pregnancy: how the mother and baby handle it during delivery
This study tests how caffeine is processed in pregnant people and how much reaches the baby when given shortly before delivery.
-
IVIG for bronchopulmonary dysplasia in infants born at 28 weeks or earlier
This trial will try intravenous immunoglobulin (IVIG) given over five days to see if it helps very preterm infants (≤28 weeks) who show early signs of bronchopulmonary dysplasia.
-
High-energy DHA/ARA-enriched human milk in the first 2 weeks to lower lung problems in extremely preterm babies
This trial tests whether giving DHA/ARA-enriched, fortified human milk in the first 14 days after birth helps extremely preterm infants breathe easier and have better lung function.
-
Reduced versus higher daily fluids to prevent bronchopulmonary dysplasia in very preterm babies
This tests whether giving smaller daily fluid volumes from day 8 of life (about 135 mL/kg/day) instead of larger volumes (about 165 mL/kg/day) lowers the chance of developing BPD or dying before 36 weeks in babies born before 30 weeks.
-
Using IVIG to treat bronchopulmonary dysplasia in premature infants
This study is testing if a special immune treatment called IVIG can help premature babies with breathing problems caused by bronchopulmonary dysplasia feel better.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.